甲福明和奥兰沙平对代谢系统的时间依赖性影响
Gizem Kurt1, Seyda T Durhan2, Mehmet Ak3
1Middle East Technical University, Department of Biological Sciences, Ankara, Turkey.
Pharmacopsychiatry
|July 10, 2025
概括
甲福明可以减少由第二代抗精神病药物 olanzapine 引起的体重增加. 早期的甲福明治疗显示出预防这些代谢副作用的前景.
科学领域:
- 药理学 药理学是指药理学的学科.
- 神经科学是一个神经科学.
- 代谢研究研究 代谢研究
背景情况:
- 第二代抗精神病药物,如奥兰扎,与显著的体重增加有关.
- 目前正在研究甲胺是否有潜力减轻这些代谢副作用.
研究的目的:
- 在大鼠模型中调查甲福明在预防奥兰扎诱导的体重增加和代谢变化的有效性.
- 评估甲胺对养行为,基因表达和代谢标记物的影响.
主要方法:
- 雄性Wistar大鼠接受了7周和14周的 olanzapine,有或没有甲福林治疗.
- 测量包括养行为,食物摄入量,体重增加,血瘦素和甘油三水平.
- 使用定量实时聚合酶链反应分析了下丘脑基因表达 (Pomc,Npy).
主要成果:
- 奥兰扎平诱导了显著的体重增加;在14周内同时服用甲胺降低了体重和食物摄入量.
- 单独使用 olanzapine 时,瘦素水平会升高,但同时使用 metformin 治疗时会降低.
- 奥兰沙平改变了下丘脑基因表达,降低了Pomc的调节,提高了Npy的调节,甲胺部分扭转了效果.
结论:
- 早期与甲福明联合治疗显著缓解了松诱导的体重增加和减少食物摄入量.
- 甲福明在早期启动时显示出预防与抗精神病治疗相关的代谢副作用的潜力.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
309
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
309
Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response
133
Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
133
Factors Affecting Drug Biotransformation: Biological
252
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
252
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
305
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
305
Factors Affecting Drug Biotransformation: Physicochemical and Chemical Properties of Drugs
383
A drug's physicochemical properties fundamentally influence its metabolism. For instance, a drug's molecular size and shape critically determine its interaction with enzymes and transporters — larger drugs may face difficulty reaching enzyme active sites, altering their metabolic pathways. The pKa of a drug, which establishes its ionization state, can impact its solubility and absorption, thereby influencing metabolism.
The drug's acidity or basicity is essential in...
The drug's acidity or basicity is essential in...
383
Oral Hypoglycemic Agents: Glinides
269
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
269


